000931757 000__ 04526cam\a2200505Ia\4500
000931757 001__ 931757
000931757 005__ 20230306151701.0
000931757 006__ m\\\\\o\\d\\\\\\\\
000931757 007__ cr\un\nnnunnun
000931757 008__ 200425s2020\\\\sz\\\\\\o\\\\\000\0\eng\d
000931757 020__ $$a9783030410087$$q(electronic book)
000931757 020__ $$a3030410080$$q(electronic book)
000931757 020__ $$z9783030410070
000931757 035__ $$aSP(OCoLC)on1152065949
000931757 035__ $$aSP(OCoLC)1152065949
000931757 040__ $$aEBLCP$$beng$$cEBLCP$$dGW5XE$$dEBLCP
000931757 049__ $$aISEA
000931757 050_4 $$aRM275
000931757 08204 $$a615.3/7$$223
000931757 08204 $$a616.079
000931757 24500 $$aImmunotherapy /$$cAung Naing, Joud Hajjar, editors.
000931757 250__ $$a3rd ed.
000931757 260__ $$aCham :$$bSpringer,$$c2020.
000931757 300__ $$a1 online resource (342 pages).
000931757 336__ $$atext$$btxt$$2rdacontent
000931757 337__ $$acomputer$$bc$$2rdamedia
000931757 338__ $$aonline resource$$bcr$$2rdacarrier
000931757 4901_ $$aAdvances in Experimental Medicine and Biology ;$$vv.1244
000931757 500__ $$aAnal Cancer
000931757 5050_ $$aIntro -- Contents -- Contributors -- 1: Overview of Basic Immunology and Clinical Application -- Innate Immune System -- Cellular Components of the Innate Immune System -- Leukocytes -- Neutrophils -- Monocytes and Macrophages -- Eosinophils -- Basophils -- Mast Cells -- Dendritic Cells -- Natural Killer Cells -- Adaptive Immune System -- Cellular Components of the Adaptive Immune System -- T Lymphocytes -- B Lymphocytes -- Immunoglobulins -- The Immune System in Action! -- Summary of the Immune Responses against Tumor Cells -- Cancer Immunotherapy -- Translational Relevance
000931757 5058_ $$aPD-L1 Expression -- Tumor-Infiltrating Lymphocytes -- Immunoscore -- T-Cell Receptor Diversity -- Mutation Load and Molecular Alterations -- Immune Gene Signature -- Cancer Immunogram -- Serum Biomarkers -- Circulating Biomarkers -- Microbiome Assessment -- Conclusion -- References -- 2: Advances in Diagnostic Procedures and Their Applications in the Era of Cancer Immunotherapy -- Introduction -- Immunohistochemistry -- IHC Applications -- Cancer Pathology Diagnostics -- Predictive Biomarker Tests -- Single-Marker Versus Multiplexed IHC -- Next-Generation Sequencing -- Flow Cytometry
000931757 5058_ $$aOther Preclinical and Clinical Diagnostics Techniques in Immunotherapy Research -- Preclinical Tumor Models in Immunotherapy Research -- Immunodeficient and Immunocompetent Mouse Models, Nude Mouse -- Xenograft Tumor Models -- Common Translational Research Techniques and their Biospecimen Requirements -- References -- 3: Immunotherapy for Melanoma -- Introduction -- Short Overview of the History of Melanoma Treatment Options up to 2011 -- High-Dose Interleukin-2 -- Chemotherapy -- Adoptive Cell Therapy (ACT) -- Immune Checkpoint Inhibitors -- Anti-CTLA-4: Ipilimumab -- Anti-PD-1 -- Nivolumab
000931757 5058_ $$aPembrolizumab -- Ipilimumab and Nivolumab in Combination -- Ipilimumab and Pembrolizumab in Combination -- Anti-PD-L1 -- Vaccination and Intratumoral Approaches -- PV-10 (Rose Bengal) -- T-VEC -- Brain Metastases and Immunotherapy -- Adjuvant Therapies -- Adjuvant Therapy with Interferon -- Adjuvant Biochemotherapy -- CPIs in the Adjuvant Setting -- The Future of Melanoma Treatment -- Indoleamine Dioxygenase (IDO) Inhibitors -- Lymphocyte-Activation Gene 3 (LAG-3) -- T-Cell Immunoglobulin-3 (Tim-3) -- OX40 -- 4-1BB -- Toll-Like Receptors (TLRs)
000931757 5058_ $$aBempegaldesleukin (NKTR-214): A CD-122-Biased IL-2 Receptor -- Melanoma Immunotherapy and the Gut Microbiome -- Conclusion -- References -- 4: Immunotherapy in Lung Cancer: From a Minor God to the Olympus -- Introduction -- Early-Stage NSCLC and Locally Advanced NSCLC -- First Line Metastatic NSCLC -- Pre-treated NSCLC -- ICIs and SCLC -- Conclusions and Future Perspectives -- References -- 5: Immunotherapy in Gastrointestinal Malignancies -- Introduction -- Gastroesophageal Cancer -- Current Evidence -- Future Strategies -- Colorectal Cancer -- Current Evidence -- Future Strategies
000931757 506__ $$aAccess limited to authorized users.
000931757 588__ $$aDescription based on print version record.
000931757 650_0 $$aImmunotherapy.
000931757 7001_ $$aNaing, Aung.
000931757 7001_ $$aHajjar, Joud.
000931757 77608 $$iPrint version:$$aNaing, Aung$$tImmunotherapy$$dCham : Springer International Publishing AG,c2020$$z9783030410070
000931757 830_0 $$aAdvances in experimental medicine and biology ;$$vv. 1244.
000931757 852__ $$bebk
000931757 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-3-030-41008-7$$zOnline Access$$91397441.1
000931757 909CO $$ooai:library.usi.edu:931757$$pGLOBAL_SET
000931757 980__ $$aEBOOK
000931757 980__ $$aBIB
000931757 982__ $$aEbook
000931757 983__ $$aOnline
000931757 994__ $$a92$$bISE